II.studio / Shutterstock.com
Argentum Pharmaceuticals can’t have a Novartis patent for a multiple sclerosis drug invalidated because it doesn’t have standing to bring the challenge, the US Court of Appeals for the Federal Circuit has ruled.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Argentum Pharmaceuticals, Novartis, Gilenya, multiple sclerosis, Teva, Actavis, KVK-Tech, ANDA, FDA, US Food and Drug Administration